Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenovirus Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

NCT05213728
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

NCT01241344
View directory record Official record
Conditions
Adenovirus Disease
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
3 Months to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Multivirus-specific Cytotoxic T Lymphocytes (mCTL)

NCT02510404
View directory record Official record
Conditions
Refractory Viral Infections
Interventions
mCTLs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
4 Weeks to 45 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 21, 2026, 3:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections

NCT04722029
View directory record Official record
Conditions
Adenovirus Infection
Interventions
Adenovirus Specific T lymphocytes
Biological
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Terminated No phase listed Observational

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

NCT02420080
View directory record Official record
Conditions
Adenovirus
Interventions
Brincidofovir
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Washinton, District of Columbia • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

NCT04453202
View directory record Official record
Conditions
Healthy
Interventions
RSV Vaccine, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
San Diego, California • Coral Gables, Florida • El Dorado, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer

NCT00583024
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
ADENOVIRUS/PSA VACCINE
Biological
Lead sponsor
David M Lubaroff
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

cAd3-Marburg Vaccine in Healthy Adults

NCT03475056
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
cAd3-Marburg vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Allogeneic Virus-specific T Cell Lines (VSTs)

NCT02510417
View directory record Official record
Conditions
Viral Infections After HSCT
Interventions
VSTs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
4 Weeks to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Donor-Derived Viral Specific T-cells (VSTs)

NCT02048332
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
Interventions
Viral specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Weeks and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
3
States / cities
Akron, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

NCT00805376
View directory record Official record
Conditions
Brain Cancer, Central Nervous System Diseases
Interventions
DNX-2401, Tumor Removal
Drug · Procedure
Lead sponsor
DNAtrix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

NCT03583606
View directory record Official record
Conditions
Ebola Disease, Immunisation
Interventions
ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00049218
View directory record Official record
Conditions
Lung Cancer
Interventions
Autologous dendritic cell-adenovirus p53 vaccine, Carboplatin, Etoposide
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

NCT03003676
View directory record Official record
Conditions
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Interventions
ONCOS-102, Cyclophosphamide, Pembrolizumab
Biological · Drug
Lead sponsor
Targovax Oy
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 21, 2026, 3:32 AM EDT
Recruiting No phase listed Observational

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

NCT06605378
View directory record Official record
Conditions
Chronic Granulomatous Disease (CGD)
Interventions
Not listed
Lead sponsor
Ensoma
Industry
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001

NCT00382408
View directory record Official record
Conditions
Respiratory Tract Diseases
Interventions
DR-5001, Placebo
Biological · Other
Lead sponsor
Duramed Research
Industry
Eligibility
17 Years and older
Enrollment
4,040 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Great Lakes, Illinois • Fort Jackson, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 21, 2026, 3:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study

NCT01971359
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Not listed
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer

NCT00003450
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Ad5CMV-p53 gene
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 21, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

NCT02998554
View directory record Official record
Conditions
Adenoviral Conjunctivitis
Interventions
SHP640, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Glendale, California • Los Angeles, California • Torrance, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

NCT04563702
View directory record Official record
Conditions
Covid19
Interventions
VXA-CoV2-1
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 54 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 21, 2026, 3:32 AM EDT
Terminated Phase 1 Interventional

This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

NCT03618953
View directory record Official record
Conditions
HPV-Associated Cancers
Interventions
Ad-E6E7, MG1-E6E7, Atezolizumab
Biological
Lead sponsor
Turnstone Biologics, Corp.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Miami, Florida • Billings, Montana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 21, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

NCT03339713
View directory record Official record
Conditions
Healthy
Interventions
Ad26.RSV.preF, Fluarix, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
60 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 21, 2026, 3:32 AM EDT
Recruiting Phase 1 Interventional

Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

NCT03425526
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Interventions
Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 3:32 AM EDT
Not listed Phase 2 Interventional

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage Iv
Interventions
OBP-301
Drug
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 3:32 AM EDT